Home/Biodexa Pharmaceuticals/Stephen Stamp

SS

Stephen Stamp

Chief Executive Officer / Chief Financial Officer

Biodexa Pharmaceuticals

Therapeutic Areas

Oncology Rare Diseases Metabolic Disease

Biodexa Pharmaceuticals Pipeline

Drug	Indication	Phase
eRapa	Familial Adenomatous Polyposis (FAP)	Phase 3
MTX240 (OPB-171775)	TKI-Resistant Gastrointestinal Stromal Tumors (GIST)	Phase 1/2
Tolimidone	Type 2 Diabetes	Phase 2

Leadership Team at Biodexa Pharmaceuticals

Chief Medical Officer

Vice President, Technology

View full Biodexa Pharmaceuticals profile